Brokerages Anticipate Aldeyra Therapeutics, Inc. (ALDX) Will Post Earnings of -$0.42 Per Share

Equities research analysts expect Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) to announce ($0.42) earnings per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Aldeyra Therapeutics’ earnings. The highest EPS estimate is ($0.36) and the lowest is ($0.50). Aldeyra Therapeutics posted earnings of ($0.38) per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 10.5%. The company is expected to announce its next quarterly earnings results on Monday, November 13th.

According to Zacks, analysts expect that Aldeyra Therapeutics will report full year earnings of ($1.67) per share for the current fiscal year, with EPS estimates ranging from ($2.12) to ($1.43). For the next financial year, analysts expect that the company will post earnings of ($1.75) per share, with EPS estimates ranging from ($2.49) to ($1.24). Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that cover Aldeyra Therapeutics.

Aldeyra Therapeutics (NASDAQ:ALDX) last released its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.35) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.37) by $0.02.

ALDX has been the subject of several research reports. Canaccord Genuity reissued a “buy” rating and set a $27.00 price objective (up from $12.00) on shares of Aldeyra Therapeutics in a research note on Wednesday. Stifel Nicolaus reissued a “buy” rating and set a $16.00 price objective on shares of Aldeyra Therapeutics in a research note on Wednesday, May 31st. Zacks Investment Research lowered Aldeyra Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, May 30th. ValuEngine raised Aldeyra Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Tuesday. Finally, HC Wainwright set a $18.00 price objective on Aldeyra Therapeutics and gave the stock a “buy” rating in a research note on Thursday, June 15th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $15.95.

TRADEMARK VIOLATION NOTICE: “Brokerages Anticipate Aldeyra Therapeutics, Inc. (ALDX) Will Post Earnings of -$0.42 Per Share” was originally reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this story on another site, it was illegally stolen and reposted in violation of international copyright legislation. The legal version of this story can be viewed at https://www.chaffeybreeze.com/2017/09/17/brokerages-anticipate-aldeyra-therapeutics-inc-aldx-will-post-earnings-of-0-42-per-share.html.

In other Aldeyra Therapeutics news, major shareholder Life Sciences Maste Perceptive bought 296,007 shares of the firm’s stock in a transaction dated Friday, June 30th. The stock was acquired at an average price of $4.60 per share, with a total value of $1,361,632.20. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 28.40% of the company’s stock.

Institutional investors have recently modified their holdings of the company. Virtu KCG Holdings LLC acquired a new stake in shares of Aldeyra Therapeutics in the second quarter worth $104,000. Renaissance Technologies LLC acquired a new stake in shares of Aldeyra Therapeutics in the first quarter worth $132,000. Hikari Power Ltd boosted its position in shares of Aldeyra Therapeutics by 186.4% in the second quarter. Hikari Power Ltd now owns 107,858 shares of the biotechnology company’s stock worth $507,000 after buying an additional 70,196 shares during the period. Sabby Management LLC acquired a new stake in shares of Aldeyra Therapeutics in the first quarter worth $898,000. Finally, Vanguard Group Inc. boosted its position in shares of Aldeyra Therapeutics by 3.2% in the second quarter. Vanguard Group Inc. now owns 304,633 shares of the biotechnology company’s stock worth $1,431,000 after buying an additional 9,407 shares during the period. 49.09% of the stock is owned by institutional investors and hedge funds.

Aldeyra Therapeutics (NASDAQ:ALDX) traded down 17.59% during trading on Friday, hitting $8.90. The stock had a trading volume of 6,112,126 shares. Aldeyra Therapeutics has a 1-year low of $3.80 and a 1-year high of $11.90. The firm’s 50-day moving average price is $4.74 and its 200-day moving average price is $4.75. The stock’s market cap is $55.58 million.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics, Inc, formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes.

Get a free copy of the Zacks research report on Aldeyra Therapeutics (ALDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aldeyra Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply